Total Valuation
Annovis Bio has a market cap or net worth of €50.97M. The enterprise value is €51.06.
Market Cap€50.97M
Enterprise Value€51.06
Share Statistics
Annovis Bio has 42,606,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,606,150
Owned by Insiders11.30%
Owned by Institutions6.63%
Financial Efficiency
Annovis Bio’s return on equity (ROE) is -1.71 and return on invested capital (ROIC) is -170.21%.
Return on Equity (ROE)-1.71
Return on Assets (ROA)-1.37
Return on Invested Capital (ROIC)-170.21%
Return on Capital Employed (ROCE)-1.70
Revenue Per Employee0.00
Profits Per Employee-4.12M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Annovis Bio is ―. Annovis Bio’s PEG ratio is 0.08.
PE Ratio―
PS Ratio0.00
PB Ratio4.22
Price to Fair Value4.22
Price to FCF-2.78
Price to Operating Cash Flow-1.20
PEG Ratio0.08
Income Statement
In the last 12 months, Annovis Bio had revenue of 0.00 and earned -28.85M in profits. Earnings per share was -1.40.
Revenue0.00
Gross Profit0.00
Operating Income-29.70M
Pretax Income-28.85M
Net Income-28.85M
EBITDA-28.85M
Earnings Per Share (EPS)-1.40
Cash Flow
In the last 12 months, operating cash flow was -43.34M and capital expenditures -5.00, giving a free cash flow of -43.34M billion.
Operating Cash Flow-43.34M
Free Cash Flow-43.34M
Free Cash Flow per Share-1.02
Dividends & Yields
Annovis Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.12
52-Week Price Change-38.11%
50-Day Moving Average1.54
200-Day Moving Average2.10
Relative Strength Index (RSI)37.45
Average Volume (3m)195.00
Important Dates
Annovis Bio upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Annovis Bio as a current ratio of 5.80, with Debt / Equity ratio of 0.00%
Current Ratio5.80
Quick Ratio5.80
Debt to Market Cap0.00
Net Debt to EBITDA0.68
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Annovis Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Annovis Bio EV to EBITDA ratio is -1.79, with an EV/FCF ratio of -2.01.
EV to Sales0.00
EV to EBITDA-1.79
EV to Free Cash Flow-2.01
EV to Operating Cash Flow-2.01
Balance Sheet
Annovis Bio has €18.73M in cash and marketable securities with €0.00 in debt, giving a net cash position of €18.73M billion.
Cash & Marketable Securities€18.73M
Total Debt€0.00
Net Cash€18.73M
Net Cash Per Share€0.44
Tangible Book Value Per Share€0.82
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Annovis Bio is €9.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€9.17
Price Target Upside499.43% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast17.78%